Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
about
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Correction: Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
P2860
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
@ast
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
@en
type
label
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
@ast
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
@en
prefLabel
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
@ast
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
@en
P2093
P2860
P50
P1433
P1476
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
@en
P2093
Hidejiro Torigoe
Hiroaki Asano
Hiroki Sato
Hirotaka Kanzaki
Ken Suzawa
Mototsugu Watanabe
Ramachandran Murali
Shinichi Toyooka
Shinichiro Miyoshi
P2860
P304
P356
10.1371/JOURNAL.PONE.0171356
P407
P577
2017-02-03T00:00:00Z